- Conditions
- Geographic Atrophy
- Interventions
- Pegcetacoplan, Sham Procedure
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 35
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 354
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dry Eye Syndrome
- Interventions
- BRM421, Placebo
- Drug
- Lead sponsor
- BRIM Biotechnology Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 4
- States / cities
- Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts + 1 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution
- Drug
- Lead sponsor
- Faes Farma, S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Torrance, California • Andover, Massachusetts + 3 more
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Transcranial Magnetic Stimulation (TMS), repetitive transcranial magnetic stimulation
- Device
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- Choriogonadotropin Alpha, biotin, Microcellulose filler
- Drug · Dietary Supplement · Other
- Lead sponsor
- Sports Medicine Research and Testing Laboratory
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Lupus Nephritis (LN)
- Interventions
- Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy
- Interventions
- 4D-150 IVT, Aflibercept IVT
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 5
- States / cities
- Hagerstown, Maryland • Eugene, Oregon • Erie, Pennsylvania + 2 more
- Conditions
- Macular Edema Secondary to Retinal Vein Occlusion
- Interventions
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
- Drug · Diagnostic Test
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 892 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 53
- States / cities
- Fullerton, California • Long Beach, California • Mountain View, California + 48 more
- Conditions
- Mucopolysaccharidosis IV A, Morquio A Syndrome, MPS IVA
- Interventions
- BMN 110 - Weekly, BMN 110 - Every Other Week
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Oakland, California • Orange, California + 7 more
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Conservative Medical Therapy (CMT), Sham PAP (Sham), Active PAP with RT Support (Active-Beh), Active PAP with Behavioral Modification (Active+Beh)
- Behavioral · Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Postoperative Pain
- Interventions
- Bolus, Basal
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
- Interventions
- Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention
- Drug · Other
- Lead sponsor
- Laboratoires Thea
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- San Francisco, California • Miami, Florida • Atlanta, Georgia + 7 more
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004%
- Drug
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Autistic Disorder
- Interventions
- sapropterin, Placebo
- Drug
- Lead sponsor
- The Children's Health Council
- Other
- Eligibility
- 3 Years to 6 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Diabetic Macular Edema
- Interventions
- Vamikibart, Ranibizumab, Sham Procedure
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 36
- States / cities
- Arcadia, California • Poway, California • Sacramento, California + 33 more
- Conditions
- Stargardt Disease 1
- Interventions
- Tinlarebant, Placebo
- Drug
- Lead sponsor
- Belite Bio, Inc
- Industry
- Eligibility
- 12 Years to 20 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Minneapolis, Minnesota • Salt Lake City, Utah
- Conditions
- Thyroid Eye Disease
- Interventions
- Batoclimab, Placebo
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 29
- States / cities
- Beverly Hills, California • Carlsbad, California • Los Angeles, California + 24 more
- Conditions
- Dry Eye Disease
- Interventions
- Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane, Vehicle
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 443 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Glendale, California • Long Beach, California + 27 more
- Conditions
- Non-infectious Anterior Uveitis
- Interventions
- Tacrolimus ophthalmic solution
- Drug
- Lead sponsor
- Novaliq GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Miami, Florida • Waltham, Massachusetts + 3 more
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- Tabirafusp tedromer, Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 910 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 9
- States / cities
- Glendale, California • Pasadena, California • St. Petersburg, Florida + 6 more
- Conditions
- Atopic Keratoconjunctivitis
- Interventions
- DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
- Drug
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 10 Years to 65 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Miami, Florida • Morrow, Georgia + 5 more
- Conditions
- Retinal Disease
- Interventions
- Finasteride, Placebo
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ocular Infections, Irritations and Inflammations
- Interventions
- KPI-121 0.25%, KPI-121 1.0%, Vehicle of KPI-121 0.25%, Vehicle of KPI-121 1.0%
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 23
- States / cities
- Artesia, California • Mission Hills, California • Rancho Cordova, California + 17 more
- Conditions
- Healthy Volunteer
- Interventions
- Urolithin A, Placebo
- Dietary Supplement
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 55 Years to 100 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland